NSD1 and acute myeloid leukemia: To gain additional insights into the biology of UBTF-TD mutant AML, we performed an RNA-sequencing analysis of 7 AML samples from UBTF-TDpos patients and 42 samples from other well established AML subgroups, i.e., t(8;21), inv16, NPM1 and in-frame CEBPAbZIP mutant patients (single and double), t(6;9) and patients with a NUP98-NSD1 fusion.